DOI QR코드

DOI QR Code

The Effect of Abraxane on Cell Kinetic Parameters of HeLa Cells

  • Gurses, Nurcan (Department of Biology, Institute of Science, Istanbul University) ;
  • Topcul, Mehmet (Department of Biology, Faculty of Science, Istanbul University)
  • Published : 2013.07.30

Abstract

Abraxane (nab-paclitaxel) is a member of the group of nano chemotherapeutics. It is approved for metastatic breast cancer and non small cell lung cancer. Trials for several cancer types including gynecological cancers, head and neck, and prostatic cancer are being studied. In this study, the antiproliferative and apoptotic effect of abraxane was evaluated on HeLa cell line originated from human cervix carcinoma. Three different doses ($D_1$=10 nM, $D_2$=50 nM, $D_3$=100 nM) were administered to HeLa cells for 24, 48 and 72 h. The 50 nM dose of abraxane decreased DNA synthesis from 4.62-0.08%, mitosis from 3.36-1.89% and increased apoptosis from 10.6-30% at 72 h. Additionally, tripolar metaphase plates were seen in mitosis preparations. In this study, abraxane effected cell kinetic parameters significantly. This results are consistent with other studies in the literature.

Keywords

Abraxane;cervical cancer;HeLa;nanodrugs;nab-paclitaxel;in vitro;$^3H$ Thymidine

References

  1. Brannon-Peppas L, Blanchette JO (2004). Nanoparticle and targeted systems for cancer therapy. Adv Drug Delivery Rev, 56, 1649-59. https://doi.org/10.1016/j.addr.2004.02.014
  2. Danhier F, Lecouturier N, Vroman B, et al (2009). Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation. J Controlled Release, 133, 11-7. https://doi.org/10.1016/j.jconrel.2008.09.086
  3. Demeure MJ, Stephan E, Gonzales P, et al (2008). Pre-clinical evidence for nab-paclitaxel efficacy in the treatment of adrenocortical cancer. J Clin Oncol, 26, 22070.
  4. Desai N, Trieu V, Yao Z, et al (2006). Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res, 12, 1317-24. https://doi.org/10.1158/1078-0432.CCR-05-1634
  5. Fader AN, Rose PG (2009). Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. Int J Gynecol Cancer, 19, 1281-3. https://doi.org/10.1111/IGC.0b013e3181a38e2f
  6. Gradishar WJ, Tjulandin S, Davidson N, et al (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol, 23, 7794-803. https://doi.org/10.1200/JCO.2005.04.937
  7. Green MR, Manikhas GM, Orlov S, et al (2006). Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol, 17, 1263-8. https://doi.org/10.1093/annonc/mdl104
  8. HTTP://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm323668.htm 16.05.2013.
  9. HTTP://www.has-sante.frportailuploaddocsapplicationpdf2011-01abraxane_ct_7088.pdf 10.02.2013.
  10. Kratz F (2008). Albumin as drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Controlled Release, 132, 171-83. https://doi.org/10.1016/j.jconrel.2008.05.010
  11. Lin LY, Karwa A, Kostelc JG, et al (2012). Paclitaxel-loaded SCK nanoparticles: an investigation of loading capacity and cell killing abilities. In Vitro Mol Pharmaceutics, 9, 2248-55. https://doi.org/10.1021/mp3000887
  12. Saunders DE, Dwayne-Lawrence W, Christensen C, et al (1997). Paclitaxel-induced apoptosis in MCF-7 breast-cancer cells. Int J Cancer, 70, 214-20. https://doi.org/10.1002/(SICI)1097-0215(19970117)70:2<214::AID-IJC13>3.0.CO;2-I
  13. Sparreboom A, Scripture CD, Treiu V, et al (2005). Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound Paclitaxel (ABI-007) and Paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res, 11, 4136-43. https://doi.org/10.1158/1078-0432.CCR-04-2291
  14. Topcul M, Cetin I (2013). Nanotechnology in the field of clinical oncology. Marmara Med J, 26, 1-4.
  15. Wiedenmann N, Valdecanas D, Hunter N, et al (2007). One hundred thirty-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain. Clin Cancer Res, 13, 1868-74. https://doi.org/10.1158/1078-0432.CCR-06-2534
  16. Yang Y, Niu X, Zhang Q, et al (2010). In vitro inhibiting effect of albumin-bound paclitaxel on human osteosarcoma cell os-732. Shandong Med J, 50, 24-26.
  17. Yang Y, Niu X, Zhang Q, et al (2012). The efficacy of Abraxane on osteosarcoma xenografts in nude mice and expression of secreted protein, acidic and rich in cysteine. Am J Med Sci, 344, 199-205. https://doi.org/10.1097/MAJ.0b013e31823e62e5
  18. Zhang C, Awasthi N, Schwartz MA, et al (2013). Superior antitumor activity of nanoparticle albumin- bound Paclitaxel in experimental gastric cancer. Plos One, 8, 1-10.

Cited by

  1. Clinical Investigation of Efficacy of Albumin Bound Paclitaxel plus Platinum Compounds as First-line Chemotherapy for Stage III/IV Squamous Non-small Cell Lung Cancer vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7453
  2. Development of Polymeric Nanopaclitaxel and Comparison with Free Paclitaxel for Effects on Cell Proliferation of MCF-7 and B16F0 Carcinoma Cells vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2335